Takeda has announced a Post-Trial Access program for patients currently enrolled in extension trials for TAK-609, a treatment for MPS II Hunter syndrome. This program will provide continued access for patients who have benefited from treatment on existing studies. This is not a new recruiting clinical trial. This information has now been updated on the National Institutes of Health website, clinicaltrials.gov. The website lists this as “Post-Trial Access Program Idursulfase-IT (HGT-2310) in Conjunction with Intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cognitive Impairment.”
Post-Trial Access TAK-609
